1. Home
  2. ACRS vs CCNE Comparison

ACRS vs CCNE Comparison

Compare ACRS & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.17

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

HOLD

Current Price

$33.96

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
CCNE
Founded
2012
1865
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
1.0B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
ACRS
CCNE
Price
$5.17
$33.96
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$10.20
★ $34.50
AVG Volume (30 Days)
★ 2.4M
110.5K
Earning Date
05-07-2026
04-20-2026
Dividend Yield
N/A
★ 2.51%
EPS Growth
★ 69.01
4.18
EPS
N/A
★ 1.79
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
$23.21
Revenue Next Year
$4.24
$7.00
P/E Ratio
★ N/A
$18.94
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$22.90
52 Week High
$6.60
$36.17

Technical Indicators

Market Signals
Indicator
ACRS
CCNE
Relative Strength Index (RSI) 39.06 50.66
Support Level $4.99 $34.07
Resistance Level $5.87 $35.17
Average True Range (ATR) 0.36 0.65
MACD -0.05 -0.04
Stochastic Oscillator 15.38 45.33

Price Performance

Historical Comparison
ACRS
CCNE

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About CCNE CNB Financial Corporation

CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.

Share on Social Networks: